Navigation Links
Responses After Completion of Therapy Increase Pixantrone Complete Remission (CR)/Unconfirmed Complete Remission (CRu) Rate to 24% and Overall Response Rate (ORR) to 40% Compared to 7% and 14% for Comparator Agents in Phase III EXTEND Trial in 3rd Line Th
Date:6/21/2009

clinical developments in the biopharmaceutical industry in general, and with pixantrone in particular, including, without limitation, the potential failure of pixantrone to prove safe and effective (including the failure to achieve the overall response rate, complete remissions and progression-free survival and the possibility of significant grade 3, 4 adverse effects, including cardiac disorders) for the treatment of relapsed, refractory indolent or aggressive NHL as determined by the FDA, the potential that priority review will not be granted by the FDA and that a decision by the FDA is not rendered in six months or in the fourth quarter of 2009, CTI's ability to continue to raise capital as needed to fund its operations, competitive factors, technological developments, costs of developing, producing and selling pixantrone, and the risk factors listed or described from time to time in CTI's filings with the Securities and Exchange Commission including, without limitation, CTI's most recent filings on Forms 10-K, 10-Q and 8-K. Except as may be required by law, CTI does not intend to update or alter its forward-looking statements whether as a result of new information, future events, or otherwise

    Media Contact:
    Dan Eramian
    T: 206.272.4343
    C: 206.854.1200
    E: media@ctiseattle.com
    www.CellTherapeutics.com/press_room

    Investors Contact:
    Ed Bell
    T: 206.282.7100
    Lindsey Jesch
    T: 206.272.4347
    F: 206.272.4434
    E: invest@ctiseattle.com
    www.CellTherapeutics.com/investors

    Medical Information Contact:
    T: 800.715.0944
    E: info@askarm.com


'/>"/>
SOURCE Cell Therapeutics, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine technology :

1. Preclinical Study Presented at AACR Annual Meeting Shows Peregrines Anti-PS Immunocytokines Can Generate Protective Immune Responses in a Highly Aggressive Breast Cancer Model
2. Delcath Updates Phase III Patient Enrollment as Pivotal Trial Accelerates, Durable Tumor Responses In Phase II Study Also Cited
3. Micromets BiTE Antibody Blinatumomab (MT103/MEDI-538) Demonstrates Durable Responses in Patients with Relapsed Non-Hodgkins Lymphoma
4. SARS Vaccine Achieves Neutralizing Responses in First U.S. Human Trial
5. Vical Pandemic Influenza Vaccines Achieve T-Cell Responses and Cross-Clade Reactivity in Humans
6. Use it or Lose it: A New Theory About Preserving Erectile Function After Prostate Surgery
7. Video: Landmark Study in The Lancet: Patients Treated With Betaseron(R) After First MS Attack Experienced Significant Delay in MS Progression
8. Post-Hoc Data Show Daily Activity Participation, Independence and Sleep Quality Improved in Adults with Moderate to Severe Rheumatoid Arthritis After Treatment with ORENCIA(R) (Abatacept)
9. Biological Psychiatry Publishes Study Showing VYVANSE Demonstrated Significant Efficacy for Treatment of ADHD for up to 12 Hours After Administration
10. AHF Seeks White House Clarification After Press Room Flap Over CDCs HIV Numbers
11. New Implantable Lenses Can Reduce the Need for Glasses After Cataract Surgery
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/14/2014)... AUSTIN, Texas , Jan. 14, 2014  Luminex Corporation (Nasdaq: ... report results for the fourth quarter of 2013 on Monday, ... scheduled for release after the close of trading. ... a conference call to discuss the operating highlights and financial ...
(Date:1/14/2014)... 2014 Dynamic Healthcare Services, Inc. ("DHS"), a portfolio company ... Progressive Home Medical Equipment, Inc. ("Progressive") of Clarion, ... the acquisition were not disclosed. Progressive is ... wide range of sleep, mobility, and respiratory products to customers ...
(Date:1/14/2014)... , a manufacturer of ergonomically designed laboratory equipment for ... Japan to sell and service the Hitachi ... will utilize its network of sales professionals throughout the ... offer assistance in application use, product benefits and features, options and ...
Breaking Medicine Technology:Luminex Corporation Fourth Quarter Earnings Release Scheduled for February 3, 2014 2Luminex Corporation Fourth Quarter Earnings Release Scheduled for February 3, 2014 3Dynamic Healthcare Services Completes Progressive Home Medical Equipment of Clarion, PA Investment 2Dynamic Healthcare Services Completes Progressive Home Medical Equipment of Clarion, PA Investment 3NuAire announces sales and service of Hitachi Koki centrifuges in North America 2
(Date:4/18/2014)... made a discovery that turns 160 years of neuroanatomy ... long known to be essential for the fast transmission ... not as ubiquitous as thought, according to a new ... Stem Cell Institute (HSCI) and the University,s Department of ... Jeff Lichtman, of Harvard,s Department of Molecular and Cellular ...
(Date:4/18/2014)... did it make you feel? According to psychologists, remembering ... as how sad you were or how embarrassed you ... can,t stop thinking about it. , When these ... the memories, rather than how you felt, is a ... effects of these memories, a new study suggests. , ...
(Date:4/18/2014)... Two Simon Fraser University psychologists have made a ... treatment of attention-deficit disorders. , This discovery opens ... may hinder or suppress a specific brain activity ... prevent distraction. , The Journal of Neuroscience ... discovery by John McDonald, an associate professor of ...
(Date:4/18/2014)... This news release is available in French . ... breakthrough could revolutionize surgical practice and regenerative medicine. A ... Molle et Chimie (CNRS/ESPCI Paris Tech) and Didier Letourneur ... and Paris 13), has just demonstrated that the principle ... used in vivo to repair soft-tissue organs and tissues. ...
(Date:4/17/2014)... inflammation in benign prostate tissue was associated with ... was found even in those with low prostate-specific ... in Cancer Epidemiology, Biomarkers & Prevention , ... Research. , An analysis of prostate tissue biopsies ... of the Prostate Cancer Prevention Trial (PCPT) found ...
Breaking Medicine News(10 mins):Health News:Finding turns neuroanatomy on its head 2Health News:Finding turns neuroanatomy on its head 3Health News:New study suggests a better way to deal with bad memories 2Health News:New study suggests a better way to deal with bad memories 3Health News:Scientists discover brain's anti-distraction system 2Health News:Innovative strategy to facilitate organ repair 2Health News:Innovative strategy to facilitate organ repair 3Health News:Chronic inflammation may be linked to aggressive prostate cancer 2Health News:Chronic inflammation may be linked to aggressive prostate cancer 3
... , , NEW YORK, Sept. 16 ... Trustees, today announced the appointment of Alan Kadish, M.D., as senior ... , PHOTO: http://www.flickr.com/photos/tourocollege/3923514965/ ... institution in the United States. The college was founded by ...
... , SEBASTOPOL, Calif., Sept. 16 As ... yerba mate is quickly catching on as the newest organic ... , (Photo: http://www.newscom.com/cgi-bin/prnh/20090916/NE76510 ) , , ... the yerba mate beverage category, is driving yerba mate into the mainstream ...
... YONKERS, N.Y., Sept. 16 Welcome to ... Consumer Reports and ConsumerReportsHealth.org cover issues pertaining ... (including natural medicines), mental health, diet and nutrition, food safety, ... products, rates the effectiveness and affordability of prescription drugs, and ...
... HONG KONG, Sept. 16 /PRNewswire-Asia/ -- ... on September 10, reporters were informed that the,First World ... Endoscopy Physicians) and the First World Endoscopy Technology Expo,will ... , Professor Zhang Yangde, the ...
... used to alleviate the shortage of available liver donors. Accurate ... donor and recipient is crucial. Scholars of different countries established ... the most accurate for Chinese adults has remained unclear. ... published on August 28, 2009 in the World Journal ...
... gastrointestinal bleeding accounts for approximately 20% of emergency ... has been used as a first-line treatment option ... be used as a safe diagnostic and treatment ... refractory to endoscopic treatment. The incidence of rebleeding ...
Cached Medicine News:Health News:Touro Appoints Alan Kadish, M.D., Senior Provost and Chief Operating Officer 2Health News:Touro Appoints Alan Kadish, M.D., Senior Provost and Chief Operating Officer 3Health News:Touro Appoints Alan Kadish, M.D., Senior Provost and Chief Operating Officer 4Health News:Guayaki Delivers Powerful Rainforest Experience with Newest Yerba Mate Beverage Innovations 2Health News:Guayaki Delivers Powerful Rainforest Experience with Newest Yerba Mate Beverage Innovations 3Health News:Consumer Reports Health News 2Health News:Consumer Reports Health News 3Health News:Consumer Reports Health News 4Health News:Consumer Reports Health News 5Health News:Consumer Reports Health News 6Health News:The First World Conference of Endoscopy Physicians will be Held December 18-20, 2009, in Hong Kong 2Health News:The First World Conference of Endoscopy Physicians will be Held December 18-20, 2009, in Hong Kong 3
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
Medicine Products: